Lancet Oncol 2009, 10:25–34.PubMedCrossRef 16. Llovet JM, Ricci S: Mazzaferro V et a1: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378–390.PubMedCrossRef 17. Baek KK, Kim JH, Uhm JE: Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011, 80:167–174.PubMedCrossRef www.selleckchem.com/products/ldn193189.html 18. Morimoto M, Numata K, Moriya S: Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. Anticancer Res 2012, 32:619–623.PubMed
19. Song T, Zhang W, Wu Q: A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol
Hepatol 2011, 23:1233–1238.PubMedCrossRef 20. Pinter M, Sieghart W, Hucke F: Prognostic factors in patients with Torin 2 advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011, 34:949–959.PubMedCrossRef 21. Lee JH, Park JY, Kim do Y: Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 2011, 31:1144–1149.PubMedCrossRef 22. Kondo S, Ojima H, Tsuda H: Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol 2012. Epub ahead of print 23. Albig AR, Neil JR, Schiemann WP: Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006, 66:2621–2629.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions JSC, FJG, BZ, YW, LJL, CHZ, LL, YLF, JW and JMX designed the study, performed the experiments, and drafted the manuscript. AP,NS and AEB designed the study and supervised the experimental work. All authors read and approved the final manuscript.”
“Introduction Lung cancer is now the most commonly diagnosed cancer and the leading cause of cancer Etofibrate death worldwide [1]. In USA, 412,230 cases had lung cancer history and the new cases estimated
in 2012 were 226,160. Most of lung cancers (56%) are diagnosed at an advanced stage as the typically asymptomatic in early stage. Lung cancer is classified into primarily two subgroups: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and the later accounts for approximately 85% of all lung cancers. Although the notable progress has been made in lung therapy, this TPX-0005 disease is still associated with a poor prognosis and has few effective treatment options. The overall 5-year survival rate for NSCLC is 17.1% [2]. The chemotherapy efficacy is varied from different individual, even in patients with similar clinical and pathologic features, the outcome varies: some complete released, some are stable or even progression. So some authors consider NSCLC as a heterogeneous disease [3].